The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic dysfunction-associated steatohepatitis (MASH) to help measure disease activity.Called AIM-NASH, it is a cloud-based tool designed to help pathologists score liver biopsy components on measures such as fat infiltration (steatosis), inflammation (hepatocellular ballooning and lobular inflammation), and […]
